Medtronic buys spinal cord stimulation therapy developer Stimgenics
Category: #health  By Mateen Dalal  Date: 2020-01-09
  • shareshare_icon
  • Twitter
  • Facebook
  • LinkedIn

Medtronic buys spinal cord stimulation therapy developer Stimgenics
  • DTM waveform will help improve the outcome for patients with chronic pain
     
  • The transaction will remain neutral to earnings per share for fiscal year 2020

Medtronic plc., a leading medical technology firm announced that it has bought Illinois-based company Stimgenics, LLC, that has developed a spinal cord stimulation (SCS) waveform broadly called Differential Target multiplexed (DTM) Spinal Cord Stimulation. The therapy is essentially delivered through the Medtronic Intellis platform and is known for its unique and new programming option that helps treat patients suffering from chronic pain.

Reportedly, the company will be presenting results covering three months of the randomized control trial (RCT) that evaluated DTM against conventional SCS at the North American Neuromodulation Society (NANS) 23rd Annual Meeting in January.

Dr. Ricardo Vallejo, the lead investigator and founder of Stimgenics, LLC as well as the director and co-founder of Illinois-based research at Millennium Pain Center, commented that research of Stimgenics has been rooted deeply within clinical science which started with animal work decades ago.

The company’s preclinical data had revealed that the modulation of glial cells and neurons are capable of returning glial cells back to their normal state and also modify their interactions with neurons that could help normalize the biological processes for breaking the pain cascade.

Vallejo added that Medtronic's acquisition can potentially improve the outcome for patients suffering from chronic pain significantly.  

Several medical society meetings have recognized the preclinical research on the neuronal-glial mechanism of action done by Stimgenics. The team has secured six awards over the span of two years for its research, out of which three of them were specific to the investigation of the DTM mechanism of action.

President for the Pain Therapies business, a part of the Restorative Therapies Group located at Medtronic, Marshall Stanton, M.D., stated that the company is dedicated to offering therapeutic options that are clinically-proven for millions of patients with chronic pain. The company believes that DTM therapy will be advancing the treatment for chronic pain backed by preclinical research and clinical evidence.

 

Source Credit- http://newsroom.medtronic.com/news-releases/news-release-details/medtronic-acquires-stimgenics-pioneer-dtmtm-novel-spinal-cord

  • shareshare_icon
  • Twitter
  • Facebook
  • LinkedIn


About Author

Mateen Dalal     twitter

Mateen Dalal

A qualified electronics and telecommunication engineer, Mateen Dalal embarked on his professional journey working as a quality and test engineer. Harnessing his passion for content creation however, Mateen pens down industry-rich articles for ReportsGO.com and a few o...

Read More..

More News By Mateen Dalal

China unveils plans to reinforce stringent safety standards for EVs

China unveils plans to reinforce stringent safety standards for EVs

By Mateen Dalal

This news comes amid rising incidences of battery fires and breaks failures. China will require automakers to have a 24-hour emergency response system to address major accidents. China is planning to reinforce strict safety standards for electri...

Facebook testing new option for cross-posting content to Instagram

Facebook testing new option for cross-posting content to Instagram

By Mateen Dalal

Facebook, Inc is reportedly testing an option that will allow users to cross-post their photos, videos, and other posts on their Instagram. It already has the feature to let people cross-post their Instagram content to Facebook. This upcoming featur...

General Motors to recoup USD 1.9 Bn from LG spent on Bolt EV recall

General Motors to recoup USD 1.9 Bn from LG spent on Bolt EV recall

By Mateen Dalal

GM will recover almost all the costs from the recall of its Bolt EV models. Despite the EV battery manufacturing mishap from LG, the two companies will continue to work together. General Motors (GM) has agreed to recover around USD 1.9 billion f...